Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08/20/08	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/20/06	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	2L 1L 1L 1L 2L 1.46Cr 2L 14.73L 6L 74.36L 6L 6L 2.36Cr	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	2Cr 1.72Cr 1.62Cr 1.48Cr 2.76Cr 190.41Cr 2.78Cr 19Cr 7.43Cr 97Cr 7.51Cr 7.35Cr 307.31Cr	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

08/20/08	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/20/06	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
21/18/21	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
11/18/11	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
27/16/27	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
30/16/30	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
11/16/11	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
09/16/09	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
08/16/08	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
30/16/30	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
23/16/23	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
22/16/22	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
19/15/19	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ROCK CREEK PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	17.04T
ELI LILLY AND COMPANY	+0.03%	-3.09%	+49.77%	+88.77%	1,00200Cr
JOHNSON & JOHNSON	-0.76%	-2.95%	+50.93%	+64.20%	65TCr
ABBVIE INC.	+0.86%	-4.13%	+19.24%	+68.35%	44TCr
ROCHE HOLDING AG	-0.80%	+0.06%	+28.73%	+35.45%	35TCr
NOVARTIS AG	-0.13%	-14.74%	+9.13%	+26.71%	26TCr
ASTRAZENECA PLC	-1.90%	-2.61%	-2.67%	+7.41%	25TCr
AMGEN INC.	-0.48%	-11.65%	+39.75%	+49.50%	21TCr
NOVO NORDISK A/S	-1.06%	-1.70%	-16.73%	-57.36%	20TCr
GILEAD SCIENCES, INC.	-0.68%	-2.65%	+25.82%	+89.06%	18TCr
Average	-0.40%	-1.86%	+22.66%	+41.34%	35.44TCr
Weighted average by Cap.	-0.21%	-2.39%	+31.83%	+55.57%

Rock Creek Pharmaceuticals, Inc. Share Price

Stocks

RCPIQ

US7720812046

Pharmaceuticals

Valuation : Rock Creek Pharmaceuticals, Inc.

Latest news : Rock Creek Pharmaceuticals, Inc.

Analysts' recommendations : Rock Creek Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

	2014	2015
Net sales	-	-
Net income	-3.85Cr -3.31Cr -3.12Cr -2.84Cr -5.32Cr -366.51Cr -5.34Cr -37Cr -14Cr -186.72Cr -14Cr -14Cr -591.53Cr	-68.45L -58.9L -55.46L -50.53L -94.55L -65Cr -94.93L -6.57Cr -2.54Cr -33Cr -2.57Cr -2.51Cr -105.12Cr
Net Debt	-45T -38.72T -36.46T -33.22T -62.16T -42.82L -62.41T -4L -2L -21.81L -2L -2L -69.11L	1.99Cr 1.71Cr 1.61Cr 1.47Cr 2.74Cr 188.95Cr 2.75Cr 19Cr 7.37Cr 96Cr 7.46Cr 7.29Cr 304.96Cr